WHO ICTRP trial
Exploration and Validation of the Targeted Treatment Protocol for Atopic…
ChiCTR2400089103 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400089103 |
|---|---|
| Public title | Exploration and Validation of the Targeted Treatment Protocol for Atopic Dermatitis in China |
| Scientific title | Exploration and Validation of the Targeted Treatment Protocol for Atopic Dermatitis in China |
| Primary sponsor | Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Atopic Dermatitis |
| Interventions | Abrocitinib 100mg:Administer 100 mg of abrocitinib orally once daily to the patient.;Abrocitinib 200mg:Administer 200 mg of abrocitinib orally once daily to the patient.;Dupixent 300mg:Administer 300 mg of Dupixent by injection every two… |
| Registration date | Sep 2, 2024 |
| Target size | Abrocitinib 100mg:66;Abrocitinib 200mg:66;Dupixent 300mg:68 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: